Lobe Sciences named lawyer Nick Karakochuk to its board on Jan. 13, 2026, granting him 3.5 million shares.

Lobe Sciences Ltd. announced on January 13, 2026, the appointment of Nick Karakochuk, a corporate and securities lawyer, to its Board of Directors. Karakochuk, bringing expertise in governance, capital markets, and complex transactions, was granted 3.5 million restricted share units. His addition supports the company’s strategic focus on disciplined execution as it advances its pipeline, including L-130 (psilocin mucate) for chronic cluster headache and other conditions. The company, which owns Altemia, Inc. and a majority stake in Cynaptec Pharmaceuticals, operates through a global network of contract providers. Forward-looking statements in the release note risks and uncertainties.